Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Aetion Acquires Synthetic Data Trailblazer Replica Analytics

Aetion, the leading regulatory-grade real-world evidence (RWE) technology provider, announced that it has acquired Replica Analytics, a pioneer in using artificial intelligence (AI) for synthetic health data generation. Replica’s AI technology generates synthetic, privacy-protected copies of real-world data (RWD) that preserve the integrity and utility of source data. Through Replica, Aetion will open up new avenues for better understanding treatment pathways, safety and effectiveness, and improve standards of care.

“Replica enhances Aetion’s technology portfolio to open access to previously inaccessible RWD,” said Dr. Jeremy Rassen, Co-Founder and President of Aetion. “Our shared belief in rooting technology innovation in scientific rigor assures that together Replica and Aetion will accelerate the impact of RWE on improving access to higher quality, more affordable healthcare, globally.”

Replica’s advanced technology expands Aetion’s offerings, including its fit-for-purpose data services, by giving customers more privacy-protected data options when using the Aetion Evidence Platform—an especially important feature in rare disease and specialty research. Fortune 50 companies already use Replica’s technology to enable fast and effective access to high utility, synthetic versions of health data across their organizations while meeting regulatory obligations and compliance with privacy laws like the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. and the General Data Protection Regulation (GDPR) in Europe. These customers include some of the most prominent life sciences research organizations in the world.

CES 2022 News: Vuzix and TeamViewer to Jointly Demonstrate Frontline AR Platform for Connected Workers at CES 2022PREDICTIONS-SERIES-2022

Related Posts
1 of 27,759

“Despite the tremendous number of valuable RWD sources, the vast majority of the world’s health data is still inaccessible to researchers because of privacy concerns,” said Dr. Khaled El Emam, Replica Analytics’ Co-Founder and CEO, now SVP & General Manager of Replica Analytics at Aetion. “Replica’s mission is to protect that privacy while making the world’s health data responsibly accessible for decision-grade RWE. Becoming part of Aetion and its ecosystem enables us to accelerate and expand that mission by deploying our technology with more data sources and in new applications.”

Aetion’s acquisition of Replica Analytics follows a series of recent high-profile announcements for the company. Most recently, the European Medicines Agency (EMA) selected Aetion to support safety and efficacy research in Europe. Also in 2021, Aetion announced a collaboration with the U.S. Food and Drug Administration (FDA) to generate RWE on inpatient COVID-19 therapies, a partnership with Paris-based AI solutions company Quinten Health to reduce research timelines, and a collaboration with England’s National Institute for Health and Care Excellence (NICE) to explore how RWE can be used to study real-world clinical effectiveness.

Recommended AI News: Liquidity Protocol Algofi Launches on Algorand, Offering a Lending Market, Stablecoin, and Liquidity Incentives

[To share your insights with us, please write to]

Comments are closed.